PURPOSE: Long-standing ulcerative colitis (UC) predisposes patients to the development of colorectal cancer, but surveillance of colitis-associated cancer by detecting the precancerous lesion dysplasia is often difficult because of its rare occurrence and normal-looking appearance. In sporadic colorectal cancer, aberrant crypt foci (ACF) have been reported by many investigators to be precursor lesions of the adenoma-carcinoma sequence. In the present study, we analyzed the genetic background of ACF to determine whether they could be precursors for dysplasia, and we examined the usefulness of endoscopic examination of ACF as a surrogate marker for surveillance of colitis-associated cancer. EXPERIMENTAL DESIGN: ACF were examined in 28 UC patients (19 patients with UC alone and 9 patients with UC and dysplasia; 2 of those patients with dysplasia also had cancer) using magnifying endoscopy. K-ras, APC, and p53 mutations were analyzed by two-step PCR RFLP, in vitro--synthesized protein assay, and single-strand conformation polymorphism, respectively. Methylation of p16 was analyzed by methylation-specific PCR. RESULTS: ACF that appeared distinct endoscopically and histologically were identified in 27 out of 28 UC patients. They were negative for K-ras, APC, and p53 mutations but were frequently positive for p16 methylation (8 of 11; 73%). In dysplasia, K-ras and APC mutations were negative but p53 mutation (3 of 5; 60%) and p16 methylation (3 of 5; 60%) were positive. There was a significant stepwise increase in the number of ACF from patients with UC alone to patients with dysplasia and to patients with cancer. Univariate and multivariate analyses showed significant correlations between ACF and dysplasia. CONCLUSIONS: We have disclosed an ACF-dysplasia-cancer sequence in colitis-associated carcinogenesis similar to the ACF-adenoma-carcinoma sequence in sporadic colon carcinogenesis. This study suggests the use of ACF instead of dysplasia for the surveillance of colitis cancer and warrants further evaluation of ACF as a surveillance marker in large-scale studies.
PURPOSE: Long-standing ulcerative colitis (UC) predisposes patients to the development of colorectal cancer, but surveillance of colitis-associated cancer by detecting the precancerous lesion dysplasia is often difficult because of its rare occurrence and normal-looking appearance. In sporadic colorectal cancer, aberrant crypt foci (ACF) have been reported by many investigators to be precursor lesions of the adenoma-carcinoma sequence. In the present study, we analyzed the genetic background of ACF to determine whether they could be precursors for dysplasia, and we examined the usefulness of endoscopic examination of ACF as a surrogate marker for surveillance of colitis-associated cancer. EXPERIMENTAL DESIGN: ACF were examined in 28 UC patients (19 patients with UC alone and 9 patients with UC and dysplasia; 2 of those patients with dysplasia also had cancer) using magnifying endoscopy. K-ras, APC, and p53 mutations were analyzed by two-step PCR RFLP, in vitro--synthesized protein assay, and single-strand conformation polymorphism, respectively. Methylation of p16 was analyzed by methylation-specific PCR. RESULTS: ACF that appeared distinct endoscopically and histologically were identified in 27 out of 28 UC patients. They were negative for K-ras, APC, and p53 mutations but were frequently positive for p16 methylation (8 of 11; 73%). In dysplasia, K-ras and APC mutations were negative but p53 mutation (3 of 5; 60%) and p16 methylation (3 of 5; 60%) were positive. There was a significant stepwise increase in the number of ACF from patients with UC alone to patients with dysplasia and to patients with cancer. Univariate and multivariate analyses showed significant correlations between ACF and dysplasia. CONCLUSIONS: We have disclosed an ACF-dysplasia-cancer sequence in colitis-associated carcinogenesis similar to the ACF-adenoma-carcinoma sequence in sporadic colon carcinogenesis. This study suggests the use of ACF instead of dysplasia for the surveillance of colitis cancer and warrants further evaluation of ACF as a surveillance marker in large-scale studies.
Authors: Dhwanil Damania; Hemant K Roy; Hariharan Subramanian; David S Weinberg; Douglas K Rex; Michael J Goldberg; Joseph Muldoon; Lusik Cherkezyan; Yuanjia Zhu; Laura K Bianchi; Dhiren Shah; Prabhakar Pradhan; Monica Borkar; Henry Lynch; Vadim Backman Journal: Cancer Res Date: 2012-04-06 Impact factor: 12.701
Authors: Cynthia A Warren; Kimberly J Paulhill; Laurie A Davidson; Joanne R Lupton; Stella S Taddeo; Mee Young Hong; Raymond J Carroll; Robert S Chapkin; Nancy D Turner Journal: J Nutr Date: 2008-12-03 Impact factor: 4.798
Authors: Frank A Orlando; Dongfeng Tan; Juan D Baltodano; Thaer Khoury; John F Gibbs; Victor J Hassid; Bestoun H Ahmed; Sadir J Alrawi Journal: J Surg Oncol Date: 2008-09-01 Impact factor: 3.454
Authors: Hyemee Kim; Nivedita Banerjee; Ryan C Barnes; Catherine M Pfent; Stephen T Talcott; Roderick H Dashwood; Susanne U Mertens-Talcott Journal: Mol Carcinog Date: 2016-04-06 Impact factor: 4.784
Authors: Yi Shen; Jun Ma; Ruilan Yan; Hongyan Ling; Xiaoning Li; Wancai Yang; John Gao; Chenfei Huang; Yiwen Bu; Yu Cao; Yingchun He; Laxiang Wan; Xuyu Zu; Jianghua Liu; Mei Chris Huang; William F Stenson; Duan-Fang Liao; Deliang Cao Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: Tom Nieto; Claire L Tomlinson; Janine Dretzke; Susan Bayliss; Malcolm James Price; Mark Dilworth; Andrew D Beggs; Olga Tucker Journal: BMJ Open Date: 2018-06-30 Impact factor: 2.692